Table 4.
Clinical relevance of the IL-10 promoter polymorphisms in patients with major trauma
| Genotypes | N | Age (years) | Gender (M/F) |
ISS | Sepsis(%) | MOD score | Cytokine (pg/ml) |
|---|---|---|---|---|---|---|---|
| -1082 | |||||||
| AA | 224 | 38.6 ± 14.1 | 177/47 | 25.6 ± 8.5 | 51.3 | 4.4 ± 2.7 | 62.0 ± 19.8 |
| AG | 73 | 37.3 ± 13.5 | 62/11 | 26.3 ± 7.5 | 38.4 | 5.4 ± 2.8 | 73.9 ± 21.3 |
| GG | 11 | 35.9 ± 20.3 | 7/4 | 27.2 ± 10.6 | 36.4 | 4.1 ± 2.9 | 86.0 ± 18.8 |
| -819 | a1 | b1 | a2, b2, c1 | ||||
| TT | 157 | 37.6 ± 13.7 | 120/37 | 25.6 ± 8.8 | 46.5 | 4.6 ± 2.6 | 56.2 ± 17.8 |
| TC | 122 | 39.6 ± 14.6 | 100/22 | 25.9 ± 8.1 | 50.8 | 4.7 ± 2.8 | 59.9 ± 20.2 |
| CC | 29 | 35.7 ± 15.1 | 26/3 | 27.1 ± 7.9 | 41.4 | 4.4 ± 2.9 | 62.4 ± 19.5 |
| -592 | |||||||
| AA | 141 | 38.2 ± 14.6 | 116/25 | 25.1 ± 7.9 | 46.1 | 4.5 ± 2.1 | 52.9 ± 16.0 |
| AC | 123 | 38.0 ± 13.2 | 98/25 | 27.1 ± 9.0 | 51.2 | 5.1 ± 3.0 | 66.8 ± 19.6 |
| CC | 43 | 36.8 ± 16.0 | 31/12 | 24.8 ± 8.0 | 44.2 | 4.1 ± 2.7 | 59.8 ± 13.1 |
| a3, c2 |
a: dominant effect (variant homozygotes +heterozygotes vs. wild homozygotes) as analyzed by ANCOVA, a1P = 0.038, a2P = 0.005, a3P = 0.001.
b: recessive effect (variant homozygotes vs. heterozygotes + wild homozygotes) as analyzed by ANCOVA, b1P = 0.088, b2P = 0.083.
c: allele dose effect as analyzed by linear regression analysis, c1P = 0.003, c2P = 0.037.
ANCOVA = analysis of covariance; F = female; ISS = Injury Severity Score; M = male; MOD = multiple organ dysfunction.